母亲接种疫苗与婴儿Covid-19住院风险
该研究采用病例对照检测阴性设计,于2021年7月1日至2022年3月8日在22个州30家医院纳入537例Covid-19住院婴儿(病例)和512例非Covid-19住院婴儿(对照),评估母亲孕期完成两剂mRNA疫苗接种对6月龄以下婴儿Covid-19住院的保护效果。总体疫苗有效性为52%(95%CI 33-65),delta变异株流行期为80%(95%CI 60-90),omicron变异株流行期为38%(95%CI 8-58);妊娠20周后接种为69%(95%CI 50-80),妊娠前20周接种为38%(95%CI 3-60)。病例婴儿中21%接受重症监护,12%接受机械通气或血管活性药物输注,2例死亡且其母亲均未接种疫苗。结论认为母亲接种两剂mRNA疫苗与婴儿Covid-19住院风险降低相关,包括重症。
要点
- 总体疫苗有效性52%(95%CI 33-65),delta期为80%(95%CI 60-90),omicron期为38%(95%CI 8-58)。
- 妊娠20周后接种有效性69%(95%CI 50-80),前20周接种38%(95%CI 3-60)。
- 病例婴儿中21%(113例)接受重症监护,12%(64例)接受机械通气或血管活性药物输注。
- 2例婴儿死于Covid-19,其母亲均未在孕期接种疫苗。
- 病例婴儿16%、对照婴儿29%的母亲在孕期完成两剂mRNA疫苗全程接种。
适用人群与场景
- 6月龄以下因Covid-19住院的婴儿(病例)及同期非Covid-19住院婴儿(对照),来自22个州30家医院,2021年7月1日至2022年3月8日纳入。
- 病例婴儿中位年龄2个月;delta期入院181例,omicron期入院356例。
研究设计与关键结果
- 研究类型:病例对照检测阴性设计;共纳入537例病例婴儿和512例对照婴儿,来自22个州30家医院。
- 暴露定义:母亲孕期完成两剂mRNA疫苗全程接种;病例婴儿16%、对照婴儿29%的母亲完成全程接种。
- 主要终点:母亲接种对婴儿Covid-19住院的疫苗有效性总体52%(95%CI 33-65),delta期80%(95%CI 60-90),omicron期38%(95%CI 8-58)。
- 按接种时机:妊娠20周后接种有效性69%(95%CI 50-80),妊娠前20周接种38%(95%CI 3-60)。
- 疾病严重程度:病例婴儿中113例(21%)接受重症监护,64例(12%)接受机械通气或血管活性药物输注;2例死于Covid-19,其母亲均未在孕期接种疫苗。
证据类型、等级与局限
- 证据类型:病例对照检测阴性设计研究,由美国疾病控制与预防中心资助。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者结论认为,母亲接种两剂mRNA疫苗与6月龄以下婴儿Covid-19住院风险降低相关,包括重症。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Infants younger than 6 months of age are at high risk for complications of coronavirus disease 2019 (Covid-19) and are not eligible for vaccination. Transplacental transfer of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after maternal Covid-19 vaccination may confer protection against Covid-19 in infants.
METHODS: We used a case-control test-negative design to assess the effectiveness of maternal vaccination during pregnancy against hospitalization for Covid-19 among infants younger than 6 months of age. Between July 1, 2021, and March 8, 2022, we enrolled infants hospitalized for Covid-19 (case infants) and infants hospitalized without Covid-19 (control infants) at 30 hospitals in 22 states. We estimated vaccine effectiveness by comparing the odds of full maternal vaccination (two doses of mRNA vaccine) among case infants and control infants during circulation of the B.1.617.2 (delta) variant (July 1, 2021, to December 18, 2021) and the B.1.1.259 (omicron) variant (December 19, 2021, to March 8, 2022).
RESULTS: A total of 537 case infants (181 of whom had been admitted to a hospital during the delta period and 356 during the omicron period; median age, 2 months) and 512 control infants were enrolled and included in the analyses; 16% of the case infants and 29% of the control infants had been born to mothers who had been fully vaccinated against Covid-19 during pregnancy. Among the case infants, 113 (21%) received intensive care (64 [12%] received mechanical ventilation or vasoactive infusions). Two case infants died from Covid-19; neither infant's mother had been vaccinated during pregnancy. The effectiveness of maternal vaccination against hospitalization for Covid-19 among infants was 52% (95% confidence interval [CI], 33 to 65) overall, 80% (95% CI, 60 to 90) during the delta period, and 38% (95% CI, 8 to 58) during the omicron period. Effectiveness was 69% (95% CI, 50 to 80) when maternal vaccination occurred after 20 weeks of pregnancy and 38% (95% CI, 3 to 60) during the first 20 weeks of pregnancy.
CONCLUSIONS: Maternal vaccination with two doses of mRNA vaccine was associated with a reduced risk of hospitalization for Covid-19, including for critical illness, among infants younger than 6 months of age. (Funded by the Centers for Disease Control and Prevention.).
参考来源
- Halasa NB, Olson SM, Staat MA, et al. Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants. N Engl J Med. 2022. PMID: 35731908. doi:10.1056/NEJMoa2204399
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。